Table of Contents
The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion in 2018 with a compound annual growth rate (CAGR) of 36.8% over the five-year period from 2013 to 2018.
This report provides:
An overview of the global market for signal transduction therapies and inhibitors
Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018
Information on approved products such as Ruxolitnib, as well as others in devlopment
Discussion of the regulatory environment which is impacting development
Relevant patent analysis
Profiles of leading companies in the industry
The intent of the report carried out by BCC Research was to assess, explore and envisage the market potential of signal transduction therapies and to review the advancement of the several candidates in their clinical developments for therapies concerning the aberrant signals through janus kinase (JAK) and phosphoinositide 3-kinases (PI3K) pathways. The emerging market analysis for the therapies associated with JAK and PI3K deviant cellular signals is brought together from the approved product performance, the notable clinical developments, the judicious collaborations for advancement of successful research, commercialization plans, huge market opportunities, etc.
The report establishes a balanced projection on the budding market of JAK and PI3K based signal transduction therapies with just two products ruxolitinib (Jakafi) and tofacitinib (Xaljanz). Ruxolitinib was approved in November 2011 for myelofibrosis while tofacitinib was approved in November 2012 for rheumatoid arthritis, respectively. The report also projects the future market for the said therapies, candidate details and their clinical development status, biomarker research, market leaders and market shares, profile of leading companies, collaboration and commercialization strategies, technology platforms and new developments, regulatory aspects, patent details, opportunities and challenges, and drivers and factors determining the signal transduction therapies market for JAK and PI3K.
The sales data for ruxolitinib and tofacitinib is secured from the germane sources that comprise the annual reports of the manufacturing companies and other data sources. Market analysis is conducted for the periods from 2011 until 2013. The report also presents the revenue forecast for the year 2018 with a drilled down analysis on the region wise data for North America (U.S. and Canada), Europe and emerging markets for the examined period.
REASONS FOR DOING THIS STUDY
Significant developments have come about in both the understanding of the complexity of signal transduction pathways such as JAK and PI3K over the past couple of years. At the same time, much progress occurred in the isolation of target specific therapies/inhibitors for the abnormal signals in those pathways. The therapies for JAK and PI3K cellular signal pathways predominantly focus on the cancer lines and inflammatory diseases after the approval of ruxolitinib (for myelofibrosis) and tofacitinib (for rheumatoid arthritis). Although other diseases categories like asthma, skin, respiratory and eye disorders are also being explored largely. The report portrays the prospective therapeutic application of the JAK and PI3K inhibitors/therapies/biomarkers from the perspective of their market opportunity, disease targets, clinical development progress, etc.
The growing market of therapies related to JAK and PI3K signal pathways have tremendous opportunity to grow since these therapies have the potential to target diseases like cancer and inflammatory diseases with no appropriate medications so far. The current therapies are capable of reducing the disease burden but cannot cure. Furthermore, there is a growing patient base worldwide for cancers and inflammatory diseases.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
The report emphasizes on the prospective remedial relevance of the signal transduction therapies for JAK and PI3K signaling pathways as well as the market demand of those therapies. The major developments in this category of medical science would be useful for the product developers/manufacturers/producers, multinationals, scientists, researchers, research universities, government and non-government organizations, and others.
SCOPE OF THE STUDY
BCC Research conducted the market evaluation, the global and regional breakdown of sales data, present and prospective application of the therapies, market forecasting, success and challenges, patent details, regulatory facet, clinical developments, market leaders and market share of the maturing market for JAK and PI3K inhibitors/therapies/biomarkers.
The sales data for the global and regional markets is validated for the present and projected values through scientific and statistical analysis. The information regarding the approved products and candidates as well as the technologies/platforms are provided based on their present/prospective application and viability.
BCC Research composed all relevant information for the report on signal thransduction therapies/inhibitors/biomarkers for JAK and PI3K signaling pathways through primary as well as secondary research methodologies. BCC Research interviewed industry practice leaders that included developers/producers of JAK and PI3K therapies, domain experts, scientists and other veterans from the industry. Furthermore, BCC Research conducted searches through several information sources. Market predictions depict the probable unit prices, usage of JAK and PI3K inhibitors/therapies/biomarkers, present-day economy and conceivable application of JAK and PI3K inhibitors/therapies/biomarkers.
BCC Research explored appropriate organizations and companies to accrue relevant data associated with JAK and PI3K inhibitors/therapies/biomarkers. The organizations were key producers and research organizations/universities of JAK and/or PI3K therapies. BCC Research also met with representatives of the companies and research groups to achieve deeper insights on the future perspectives of signal transduction therapies for JAK and PI3K signaling pathways.
BCC Research reviewed scientific journals, booklets, research papers and articles, company white papers, pharmaceutical and other relevant newsletters, science digests, online medical libraries, medical and pharmaceutical blogs, news feeds, medical papers and journals, newsletters, company literature and financial reports, product literature, periodicals, abstracts, regulatory aspects, technical articles, bulletins, patent files, pharmaceutical biopharmaceutical and medicine databases, etc.
Get Industry Insights. Simply.
Talk to Ahmad
+1 718 618 4302
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...
PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 Summary Systemic Lupus Erythematosus (SLE) is a systemic inflammatory autoimmune disease ...
PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2025 Summary Ulcerative Colitis (UC) is a type of chronic IBD that causes inflammation and ulcers in the innermost lining of ...